Radius Health has been granted a patent for various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms. The patent also discloses the use of these forms for cancer treatment. GlobalData’s report on Radius Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Radius Health, Microneedles for transdermal drug delivery was a key innovation area identified from patents. Radius Health's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Polymorphic forms of rad1901-2hcl for cancer treatment
A recently granted patent (Publication Number: US11708318B2) discloses a solid form of RAD1901-2HCl, a compound used in the treatment of breast cancer and ovarian cancer. The patent describes the specific characteristics of this solid form, including its X-ray powder diffraction pattern and its thermographic properties.
According to the patent claims, the solid Form 2 of RAD1901-2HCl has an X-ray powder diffraction pattern that includes peaks at specific angles, such as 6.3 degrees 2?±0.2 degree 2?, 12.5 degrees 2?±0.2 degree 2?, and 15.4 degrees 2?±0.2 degree 2?, at a relative humidity of 0%. Additionally, the diffraction pattern may also include a peak at 18.3 degrees 2?±0.2 degree 2? and/or 13.4 degrees 2?±0.2 degree 2?.
The patent also mentions that the solid Form 2 of RAD1901-2HCl exhibits specific thermographic properties. It has a differential scanning calorimetry (DSC) thermogram as shown in the bottom graph of FIG. 9 and a thermogravimetric analysis (TGA) as shown in the top graph of FIG. 9.
Furthermore, the patent claims cover the use of the solid Form 2 of RAD1901-2HCl in pharmaceutical compositions for the treatment of breast cancer and ovarian cancer. These compositions may include one or more pharmaceutically acceptable excipients.
The patent also discloses a method of treating breast cancer or ovarian cancer by administering a therapeutically effective amount of the solid Form 2 of RAD1901-2HCl to a patient in need. The method can be particularly useful for treating ER+ breast cancer or ovarian cancer that is resistant to endocrinological treatment. The endocrinological treatment may involve the use of various drugs, such as Selective Estrogen Receptor Degraders (SERDs), aromatase inhibitors, selective estrogen receptor modulators (SERMs), Human Epidermal Growth Factor Receptor 2 (Her2) inhibitors, chemotherapeutic agents, cdk4/6 inhibitors, m-TOR inhibitors, angiogenesis inhibitors, or rituximab.
In some cases, the method may also involve the administration of a cdk4/6 inhibitor and/or an m-TOR inhibitor, such as palbociclib, ribociclib, abemaciclib, everolimus, or a combination thereof.
Overall, this granted patent provides valuable information about a specific solid form of RAD1901-2HCl and its potential use in the treatment of breast cancer and ovarian cancer, particularly in cases where the cancer is resistant to endocrinological treatment.
To know more about GlobalData’s detailed insights on Radius Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
